General Announcement::Healthway Medical to launch Sinopharm COVID-19 Vaccine from 8 September 2021

HEALTHWAY MEDICAL TO LAUNCH SINOPHARM COVID-19

VACCINE FROM 8 SEPTEMBER 2021

OUE sponsors full vaccination for first 1,000 seniors aged 60 and above

SINGAPORE, 7 September 2021 - Healthway Medical Corporation Limited ("HMC" or "Healthway") will begin to administer the Sinopharm COVID-19 vaccine at selected HMC General Practitioner (GP) clinics in Singapore from Wednesday, 8 September 2021.

HMC, through a sponsorship by SGX Mainboard-listed real estate group OUE Limited ("OUE"), will make available both doses of the Sinopharm vaccine free of charge for the first 1,000 seniors aged 60 and above who have registered and confirmed their interest (cut-off date for those age 60 and above on 1 September 2021). This initiative is in support of the government's efforts to boost COVID-19 vaccination take-up rate among seniors who are at higher risk of falling critically ill if they are infected.

HMC has received overwhelming interest from the public for the Sinopharm vaccine. Those who have previously registered their interest for the vaccine have been invited to book their appointments. Others who wish to receive the vaccine can register their interest on www.healthwaymedical.com/sinopharm-covid-19-vaccination.Confirmation is subject to availability of stock.

The Sinopharm vaccine will first be offered at three HMC GP clinics and progressively be rolled out to more HMC clinics in the coming weeks. By tapping on its vast network of clinics in Singapore, HMC aims to make it possible for people to receive the vaccine by heading down to a HMC clinic nearest to their homes. The two-dose vaccine will be priced at $99, inclusive of GST.

The Sinopharm vaccine is administered in two doses given three to four weeks apart. It is approved for use for anyone aged 18 years and above with no history of anaphylaxis and who is not pregnant. Unlike Pfizer-BioNTech/Comirnaty and Moderna that are messenger RNA (mRNA) vaccines, Sinopharm uses an inactivated virus to elicit protection against the COVID-19 virus. According to the World Health Organization (WHO), the vaccine has an estimated 79 per cent efficacy against symptomatic and hospitalised disease.1

The Health Sciences Authority (HSA) approved applications for private hospitals and clinics to import Sinopharm through the Special Access Route on 28 July 20212, following authorisation of the vaccine

1. The Sinopharm COVID-19 vaccine: What you need to know. World Health Organization. Accessed 01 September 2021.https://www.who.int/news-room/feature-stories/detail/the-sinopharm-covid-19-vaccine-what-you-need-to-know
2. 11 Singapore private healthcare providers allowed to bring in Sinopharm COVID-19 vaccine. CNA. Accessed 01 September 2021.https://www.channelnewsasia.com/singapore/sinopharm-covid-19-hsa-special-access-route-vaccine-sinovac-2069191

6 Shenton Way #10-09, OUE Downtown 2 Singapore 068809 | D (65) 6323 4415 | F (65) 6235 0809 | healthwaymedical.com

Healthway Medical Corporation Ltd. UEN: 200708625C

by WHO for emergency use listing on 7 May 20213. It is produced by the Beijing Bio-Institute of Biological Products, a subsidiary of China National Biotech Group.

"Healthway is delighted to bring in the Sinopharm COVID-19 vaccine under the Special Access Route and we aim to make the vaccines readily available and accessible to the public. We are grateful for the strong support from OUE to sponsor vaccinations for the first 1,000 seniors aged 60 years and older who have confirmed their interest. Through this initiative, we hope to contribute to the national effort to get as many people vaccinated as possible, especially our seniors, who are more at risk. The Sinopharm vaccine, which uses an inactivated virus, enables segments of our elderly population who are not eligible to take the mRNA vaccines to now get inoculated" said Abram Suhardiman, Executive Director and Deputy Chief Executive Officer, HMC.

"OUE is pleased to partner with Healthway to sponsor vaccines for 1,000 of our seniors in support of national efforts to get the elderly population fully inoculated. Through this contribution, we hope that seniors who have not yet gotten their vaccination will come forward and register for the vaccine" added Brian Riady, Deputy Chief Executive Officer, OUE.

Providing the Sinopharm vaccine is HMC's latest initiative to support the fight against the COVID-19 pandemic in Singapore. Other efforts include providing Antigen Rapid Test (ART) and Polymerase Chain Reaction (PCR) tests at most of its GP clinics, as well as offering pre-departure testing (PDT) services at its clinics island wide. HMC also operates several vaccination centres and a mobile team in support of the national vaccination programme.

-End-

About Healthway Medical Corporation

HMC (SGX-ST: Healthway Med) is a leading private healthcare provider with one of the largest networks of clinics and medical centres in Singapore. HMC is committed to providing accessible, affordable, and quality medical services to patients. With presence in most parts of Singapore including many private hospitals, HMC offers comprehensive medical services including General Practitioner & family medicine clinics, health screening, adult specialists, baby & child specialists, dental services, and allied healthcare services. For the latest news from HMC, visit www.healthwaymedical.com.

This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor"). This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "SGX-ST") and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

3 WHO lists additional COVID-19 vaccine for emergency use and issues interim policy recommendations. World Health Organization. Accessed 01 September 2021.https://www.who.int/news/item/07-05-2021-who-lists-additional-covid-19-vaccine-for-emergency-use-and-issues-interim-policy-recommendations

6 Shenton Way #10-09, OUE Downtown 2 Singapore 068809 | D (65) 6323 4415 | F (65) 6235 0809 | healthwaymedical.com

Healthway Medical Corporation Ltd. UEN: 200708625C

The contact person for the Sponsor is Ms Foo Jien Jieng, 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, [e-mail].

Media Contacts

Jordan Isac

Vice President (HR & Communications)

Healthway Medical Corporation

Tel: [phone]

Email:

[e-mail]

6 Shenton Way #10-09, OUE Downtown 2 Singapore 068809 | D (65) 6323 4415 | F (65) 6235 0809 | healthwaymedical.com

Healthway Medical Corporation Ltd. UEN: 200708625C